Please Note: The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

* Production of this program book has been made possible through a financial contribution from the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.
CONTENTS

PAGE

WELCOME MESSAGES ........................................ 2–3

CONFERENCE ORGANIZERS ......................... 4–7

CONFERENCE INFORMATION ..................... 8–11

SATELLITE SESSIONS ............................... 12–14

PROGRAM
  Tuesday, 28 September 2010 .................... 15–16
  Wednesday, 29 September 2010 ................. 17–29
  Thursday, 30 September 2010 .................. 31–43
  Friday, 1 October 2010 ........................ 45–49

OMNI HOTEL AT CNN CENTER
  Meeting Rooms ........................................ 55
  Floor Plan ........................................... 55

PROGRAM AT A GLANCE ......................... Back Cover

ABBREVIATIONS
  Late Breaker ................................ LB
  Oral Abstract ................................. OA
  Opening Session ......................... OS
  Plenary Sessions ..................... PL
  Posters ....................................... P
  Round Table Discussion ........ RT
  Symposia .................................. S

Save the Date

AIDS VACCINE 2011
Bangkok, Thailand

12 – 15 September 2011
Dear Friends and Colleagues:

Welcome to AIDS Vaccine 2010! We are truly honored to host the 10th anniversary of the world’s premier meeting on HIV vaccines and to welcome you to Atlanta, a vibrant center of HIV/AIDS research. AIDS Vaccine 2010 will continue the tradition of highlighting discovery research, the foundation for vaccine development, and clinical trials, the ultimate test of success. Moreover, the meeting will look to the future where, pre-exposure prophylaxis, microbicides and other biomedical prevention approaches, will complement vaccines as prevention strategies.

The week’s program features leaders from around the globe. Health and Human Services Secretary Kathleen Sebelius, CDC Director Thomas Frieden, and NIAID Director Anthony Fauci will address the conference. Three plenary sessions highlight novel approaches to vaccine development, lessons from basic science studies on the pathogenesis of HIV infection, and the latest information from clinical trials. Forty-one invited speakers will present cutting-edge data in nine symposia, while a round table discussion will address the integration of prevention and vaccine trials. Finally, 11 oral abstract sessions and more than 500 posters will undoubtedly encourage debate, discussion, and innovation.

AIDS Vaccine 2010 will create opportunities for the mentoring of young investigators, with 120 conference scholarships to promising young researchers from around the world, as well as five Young Investigator Awards. For the first time, we welcome a cohort of undergraduate science scholars from across the country, who we anticipate will be energized to join us in our pursuit of an effective vaccine. Building a strong pipeline of scholars is critical for the future success of our field.

We thank the Global HIV Vaccine Enterprise for their leadership and support and our conference sponsors without whom this event could not take place. And finally, we salute and thank you, the scientists, clinicians, and community leaders who are working to make an HIV vaccine a reality.

Welcome again, as you join us in celebrating a decade of collaboration, education, and the spirited exchange of scientific ideas, all with the purpose of advancing the science of HIV vaccines.

Eric Hunter
Chair

Carlos Del Rio
Co-Chair

James Curran
Co-Chair

Harriet Robinson
Co-Chair
August 12, 2010

Dear AIDS Vaccine 2010 Conference Attendee:

The Office of National AIDS Policy sends our greetings to the scientists, clinicians, public health experts, and representatives of community based organizations who are attending the AIDS Vaccine 2010 Conference in Atlanta, Georgia.

President Obama is committed to fighting the HIV/AIDS epidemic here at home and around the world. The recently released National HIV/AIDS Strategy for the United States is intended to be a roadmap for moving the Nation forward in addressing the domestic HIV epidemic. To accomplish the Strategy’s goals of reducing HIV incidence, increasing access to care, and reducing HIV related health disparities, we must undertake a more coordinated national response to the HIV epidemic. The Strategy recognizes the importance of HIV/AIDS vaccines among other methods to combat HIV/AIDS and the Administration remains committed to furthering vaccine research.

There have been exciting gains in HIV vaccine research in the past year and my office looks forward to hearing more positive news as we continue research to prevent and to cure HIV.

Thank you for your commitment to this work.

Jeffrey S. Crowley
Director, Office of National AIDS Policy
CONFERENCE ORGANIZERS

CHAIR
Eric Hunter Emory University, USA

CO-CHAIRS
James Curran Emory University, USA
Carlos del Rio Emory University, USA
Harriet Robinson GeoVax, Inc. USA

LOCAL ORGANIZING COMMITTEE

Susan Allen Emory University, USA
John Altman Emory University, USA
Rama Rao Amara Emory University, USA
Aftab Ansari Emory University, USA
John Beal AIDS Vaccine Bike Trek, USA
Deborah Birx Centers for Disease Control and Prevention, USA
Jerry Blackwell Emory University, USA
Vincent Bond Morehouse School of Medicine, USA
Salvatore Butera Centers for Disease Control and Prevention, USA
C. Michael Cassidy Georgia Research Alliance, USA
Robert Chen Centers for Disease Control and Prevention, USA
Richard Compans Emory University, USA
Max Cooper Emory University, USA
James E. Crowe, Jr. Vanderbilt University Medical Center, USA
Cynthia Derdeyn Emory University, USA
Dázon Dixon Diallo Sisterlove, Inc., USA
Srilatha Edupuganti Emory University, USA
Joe Eron University of North Carolina School of Medicine, USA
Paula Frew Emory University, USA
David Garber Emory University, USA
Paul Goepfert University of Alabama at Birmingham School of Medicine, USA
Michael Hendry Centers for Disease Control and Prevention, USA
Spyros Kalams Vanderbilt University Medical Center, USA
Patrick Kelly Emory CFAR Community Advisory Board, USA
David Margolis University of North Carolina School of Medicine, USA
Timothy Mastro Family Health International, USA
David Montefiori Duke University School of Medicine, USA
Mark Mulligan Emory University, USA
Saad Omer Emory University, USA
Bali Pulendran Emory University, USA
LOCAL ORGANIZING COMMITTEE (cont.)

George Shaw  
University of Alabama at Birmingham, USA

Paul Spearman  
Emory University, USA

Francois Villinger  
Emory University, USA

Kent Weinhold  
Duke University School of Medicine, USA

SCIENTIFIC ORGANIZING COMMITTEE

Alash‘le Abimiku  
University of Maryland, Biotech Institute, USA

Rafi Ahmed  
Emory University, USA

Galit Alter  
Ragon Institute of MGH, MIT and Harvard, USA

Marcus Altfeld  
Harvard Medical School, USA

Brigitte Autran  
Hôpital Pitié-Salpêtrière, UPMC, France

Muhammad Bakari  
Muhimbili University College of Health Sciences, East Africa

Françoise Barré-Sinoussi  
Institut Pasteur, France

Dan Barouch  
Beth Israel Deaconess Medical Center, USA

Alan Bernstein  
Global HIV Vaccine Enterprise, USA

Susan Buchbinder  
University of California, San Francisco, USA

Dennis Burton  
The Scripps Research Institute, USA

Max Cooper  
Emory University, USA

Lawrence Corey  
HIV Vaccine Trials Network, USA

James Curran  
Emory University, USA

Paul de Bakker  
Brigham and Women’s Hospital, Harvard, USA

Carlos del Rio  
Emory University, USA

Jacques Fellay  
Duke University, USA

Barney Graham  
Vaccine Research Center, NIAID, USA

Tomas Hanke  
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, UK

Catherine Hankins  
UNAIDS, Switzerland

Alexandre Harari  
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Barton Haynes  
Duke University, USA

Eric Hunter  
Emory University, USA

Margaret (Peggy) Johnston  
NIH/NIAID, USA

Pontiano Kaleebu  
Uganda Virus Research Institute, Uganda

Wayne Koff  
International AIDS Vaccine Initiative (IAVI), USA

Bette Korber  
Los Alamos National Laboratory, USA

Roger Le Grand  
CEA, France

Yves Levy  
French National Agency for Research on AIDS and Viral Hepatitis, France

Amapola Manrique  
Global HIV Vaccine Enterprise, USA

John Mascola  
Vaccine Research Center NIAID, USA

Timothy Mastro  
Family Health International, USA

Bonnie Mathieson  
Office of AIDS Research, USA
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Souleymane Mboup</td>
<td>Family Health International, USA</td>
</tr>
<tr>
<td>Julie McElrath</td>
<td>University of Washington, USA</td>
</tr>
<tr>
<td>James McIntyre</td>
<td>University of Witwatersrand, South Africa</td>
</tr>
<tr>
<td>Andrew McMichael</td>
<td>Weatherall Institute of Molecular Medicine, UK</td>
</tr>
<tr>
<td>Nelson Michael</td>
<td>US Military HIV Research Program/Walter Reed Army Institute of Research, USA</td>
</tr>
<tr>
<td>Lynn Morris</td>
<td>National Institute for Communicable Diseases, South Africa</td>
</tr>
<tr>
<td>Gary Nabel</td>
<td>Vaccine Research Center NIAID, USA</td>
</tr>
<tr>
<td>Peter Ndumbe</td>
<td>University of Buea, Cameroon</td>
</tr>
<tr>
<td>John Nkengasong</td>
<td>Centers for Disease Control and Prevention, USA</td>
</tr>
<tr>
<td>Michel Nussenzweig</td>
<td>The Rockefeller University, USA</td>
</tr>
<tr>
<td>Saladin Osmanov</td>
<td>WHO–UNAIDS HIV Vaccine Initiative, USA</td>
</tr>
<tr>
<td>Giuseppe Pantaleo</td>
<td>Centre Hospitalier Universitaire Vaudois, Switzerland</td>
</tr>
<tr>
<td>JoAnn Passmore</td>
<td>University of Cape Town, South Africa</td>
</tr>
<tr>
<td>Louis Picker</td>
<td>Oregon Health and Science University, USA</td>
</tr>
<tr>
<td>Punnee Pitisuttithum</td>
<td>Faculty of Tropical Medicine Mahidol University, Thailand</td>
</tr>
<tr>
<td>Rino Rappuoli</td>
<td>Novartis, Italy</td>
</tr>
<tr>
<td>Harriet Robinson</td>
<td>GeoVax, Inc., USA</td>
</tr>
<tr>
<td>Morgane Rolland</td>
<td>University of Washington, USA</td>
</tr>
<tr>
<td>Nina Russell</td>
<td>The Bill &amp; Melinda Gates Foundation, USA</td>
</tr>
<tr>
<td>Jeffrey Safrit</td>
<td>The Elizabeth Glaser Pediatric AIDS Foundation, USA</td>
</tr>
<tr>
<td>Eric Sandström</td>
<td>Karolinska Institutet, Sweden</td>
</tr>
<tr>
<td>Olivier Schwartz</td>
<td>Institut Pasteur, France</td>
</tr>
<tr>
<td>Rafick-Pierre Sekaly</td>
<td>Vaccine and Gene Therapy Institute, USA</td>
</tr>
<tr>
<td>Yiming Shao</td>
<td>Department of Virology and Immunology, Chinese Center for Disease Control, China</td>
</tr>
<tr>
<td>Robin Shattock</td>
<td>St. George's Hospital, UK</td>
</tr>
<tr>
<td>Guido Silvestri</td>
<td>Emory University, USA</td>
</tr>
<tr>
<td>Ralph Steinman</td>
<td>The Rockefeller University, USA</td>
</tr>
<tr>
<td>Ron Swanstrom</td>
<td>University of North Carolina, USA</td>
</tr>
<tr>
<td>Jim Tartaglia</td>
<td>sanofi pasteur, Canada</td>
</tr>
<tr>
<td>Amalio Telenti</td>
<td>University Hospital and University of Lausanne, Switzerland</td>
</tr>
<tr>
<td>Bruce Walker</td>
<td>Ragon Institute of MGH, MIT &amp; Harvard, USA</td>
</tr>
<tr>
<td>Mitchell Warren</td>
<td>AVAC, USA</td>
</tr>
<tr>
<td>Anna–Lise Williamson</td>
<td>University of Cape Town, South Africa</td>
</tr>
</tbody>
</table>
AIDS VACCINE STEERING GROUP

Alan Bernstein  
Global HIV Vaccine Enterprise, USA  
(Chair)

Jean François Delfraissy  
French National Agency for Research on AIDS and Viral Hepatitis, France  
(Chair, AIDS Vaccine 2009)

José Esparza  
The Bill & Melinda Gates Foundation, USA

Catherine Hankins  
UNAIDS, Switzerland

Barton Haynes  
Duke University and the Center for AIDS Research for HIV/AIDS Vaccine Institute, USA

Eric Hunter  
Center for AIDS Research, Emory University, USA  
(Chair, AIDS Vaccine 2010)

Margaret (Peggy) Johnston  
National Institutes of Health, USA

Pontiano Kaleebu  
Uganda Virus Research Institute, Uganda

Yves Levy  
French National Agency for Research on AIDS and Viral Hepatitis, France

Siobhan Malone  
The Bill & Melinda Gates Foundation, USA

Bonnie Mathieson  
National Institutes of Health, USA

Margaret McCluskey  
United States Agency for International Development, USA

Rino Rappuoli  
Novartis, Italy

Manuel Romaris  
European Commission, Belgium

Pratap Singhasivanon  
Mahidol University, Thailand  
(Chair, AIDS Vaccine 2011)

Steve Wakefield  
HIV Vaccine Trials Network, USA

CONFERENCE COMMUNICATIONS AND MEDIA RELATIONS

Mark Aurigemma (communications consultant)

Jennifer Brunet (Global HIV Vaccine Enterprise)

Myra Ozaeta (Global HIV Vaccine Enterprise)

CONFERENCE SECRETARIAT

Conference Solutions  
2545 SW Spring Garden Street, Suite 150  
Portland, Oregon  
97219 USA  
+1.503.244.4294  
AIDSVaccine@ConferenceSolutionsInc.com
Conference Goals
The annual AIDS Vaccine conference is the premier forum for the exchange of scientific information relating to the difficult task of developing safe and effective vaccines against HIV. Organized under the aegis of the Global HIV Vaccine Enterprise, the goals of the meeting are to: (i) provide a venue for an international exchange of information in HIV vaccine research and development; (ii) cross-fertilize scientific areas of research; (iii) increase coordination and ongoing communication among international groups; and (iv) monitor ongoing progress in the field.

Conference Venue
The Omni Hotel at CNN Center
100 CNN Center
Atlanta, Georgia 30303
Phone: +1.404.659.0000
Fax: +1.404.525.5050
Check-in: 15:00
Check-out: 12:00

Conference Registration Desk
Grand Ballroom Foyer, North Tower M4
Tuesday, 28 September 08:00 – 19:00
Wednesday, 29 September 07:30 – 18:00
Thursday, 30 September 08:00 – 18:00
Friday, 1 October 08:00 – 13:00

Please note: Name badges must be worn for admittance to all conference functions. Access will be restricted by security.

Speaker Check-In
Walnut Room, North Tower M3
All presenting authors must hand in their final presentation at speaker check-in during the designated days and times noted below. Computers will be provided and equipped as follows: MAC computers with MAC OS 10.6, Microsoft Office Mac Pro 2008 and PCs with Windows XP PRO and Office. Presentations may be submitted on CD or USB stick. PowerPoint is the only accepted format. Personal laptops may not be used.

Conference Meals
The following meals are included in your conference registration: the welcome reception on Tuesday, continental breakfast on Wednesday, Thursday and Friday, lunch on Wednesday and Thursday, the banquet on Wednesday evening, and the Thursday poster reception.

By Invitation Only: Canada Breakfast
Redwood Room, North Tower, M1
Thursday, 30 September 07:00 – 08:30

For more information, contact MaryLouise.Goodie@international.gc.ca
Confidential Information

Certificate of Attendance
There is a removable certificate of attendance in the back of the abstract book.

Poster Presentations
International Ballroom, North Tower M2

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, 28 Sept</td>
<td>14:00 – 21:00</td>
<td>Set-Up</td>
</tr>
<tr>
<td>Wednesday, 29 Sept</td>
<td>14:30 – 16:00</td>
<td>Viewing and coffee break</td>
</tr>
<tr>
<td>Thursday, 30 Sept</td>
<td>15:00 – 16:00</td>
<td>Session 01: Even numbered posters and coffee break</td>
</tr>
<tr>
<td>Thursday, 30 Sept</td>
<td>18:30 – 19:30</td>
<td>Session 02: Odd numbered posters and reception</td>
</tr>
<tr>
<td>Thursday, 30 Sept</td>
<td>20:30 – 21:00</td>
<td>Dismantle</td>
</tr>
</tbody>
</table>

The International Ballroom will be open for general viewing of the posters from 14:00 until 21:00 Tuesday and from 07:00 – 21:00 on Wednesday and Thursday. All posters must be removed at the conclusion of the reception, Thursday, 30 September.

Publication of Abstracts
AIDS Research and Human Retroviruses
Accepted abstracts will be published as an open access online supplement in AIDS Research and Human Retroviruses at the conclusion of the conference on Friday, 1 October 2010. To access the publication go to http://www.liebertonline.com/aid

Webcasting and Presentation Archives
The AIDS Vaccine 2010 opening, closing, and plenary sessions, the round table discussion and the special session will be webcast within 24 hours of presentation. To view the webcasts, visit www.hivvaccineenterprise.org/conference/2010/webcasting.php. Approved symposia and abstract presentation slides will be archived on the conference website by 15 October.

Banquet at the Georgia Aquarium
Wednesday, 29 September
225 Baker Street
Atlanta, Georgia, 30313
+1.404.581.4000

The world's largest and most engaging aquarium is a short five minute walk from the Omni Hotel. Join us Wednesday, 29 September for an enjoyable evening with friends and colleagues. Printed directions are available at the conference registration desk.

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private Aquarium Viewing</td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td>Reception</td>
<td>19:00 – 19:30</td>
</tr>
<tr>
<td>Dinner</td>
<td>19:30 – 21:00</td>
</tr>
<tr>
<td>Remarks, James Curran</td>
<td>20:15 – 20:30</td>
</tr>
<tr>
<td>Dance and Cash Bar</td>
<td>20:30 – 23:30</td>
</tr>
</tbody>
</table>
Internet Café
International Ballroom Foyer, North Tower M2
The internet café will be open from Tuesday, 28 September – Friday, 1 October.

Internet Access
Complimentary wireless internet access is provided by the conference in the North Tower M1 – M4.
Wireless access code: AV2010ATL
Internet access is complimentary in all AIDS Vaccine guest rooms reserved at the group rate. To access the in-room internet, open your web browser. The Omni Hotel at CNN Center Internet Welcome Page will be displayed. On the right side of your screen enter your last name and room number and accept the Terms & Conditions. If you experience any challenges connecting, kindly utilize the hotel 24 hour technical support at +1.877.206.6316.

Mobile Phone Policy
Please ensure your mobile phone is turned off during all sessions so as not to disrupt the presenters and other conference attendees.

No Smoking Policy
The Omni Hotel at CNN Center is a non-smoking hotel.

Language
English is the official language of the conference.

Time Zone
Atlanta is on Eastern Daylight Time (EDT) until Sunday, 7 November. EDT is UTC/GMT -5 hours.

Currency
The U.S. dollar is the official currency of the United States and is normally abbreviated as the dollar sign, $, USD or US$.

Sales Tax
Atlanta has a sales tax of 8% on consumed goods, a tax of 4% on groceries and a 15% tax on hotel rooms.

Medical Assistance
In case of emergency, please dial 911 from a hotel house phone. The call will be routed through hotel security and will help enable the medics to pinpoint the exact location of the emergency. House phones are located in the lobby of every floor.

Insurance/Liability
The conference organizers cannot accept liability for injuries or losses arising from accidents or other situations during or as a consequence of the conference.
Transportation from Your Hotel to the Airport by Shuttle

Atlanta Airport Shuttle Connection
Reservations
Phone: +1.404.762.3007

The Conference has negotiated group rates with the Atlanta Airport Shuttle Connection of $14.50/one way and $27.00/round trip. The shuttle runs from 06:00 – 24:00 (midnight). Reservations are required 24 hours in advance.

Conference Evaluation

A short evaluation form was distributed in your conference bag. Please complete the form and return it to the conference registration desk. If you prefer to complete the evaluation electronically, an email with a link to the online evaluation will be sent on Friday, 1 October.

Surplus Conference Material Donations

Surplus conference materials, such as bags and notebooks, will be donated to Jerusalem House, www.jerusalemhouse.org, a non-profit located in Atlanta, Georgia. Jerusalem House provides over 50% of Atlanta’s permanent, supportive housing designated for homeless and low-income individuals and families affected by HIV/AIDS. The 220 residents of Jerusalem House reside in either one of two facilities-based housing programs or in the scattered site program which is the largest of its kind in the United States. Donations can be left at the conference registration desk.

The Names Project Foundation/AIDS Memorial Quilt

AIDS Vaccine 2010 is honored to display the AIDS Memorial Quilt in recognition of those affected by HIV/AIDS.

Founded in 1987, The AIDS Memorial Quilt is a powerful tool for use in preventing new HIV infections, and the largest ongoing community arts project in the world. The 54-ton, internationally celebrated, Nobel Prize-nominated AIDS Memorial Quilt is now nationally headquartered in Atlanta. The AIDS Memorial Quilt is unlike any monument ever created. It began with a single panel of fabric and a single name, which is now joined by tens of thousands of panels created one at a time to honor, mourn and remember loved ones lost to HIV/AIDS.

For more information on the work of the NAMES Project, please go to www.aidsquilt.org.
SATELLITE SESSIONS
Tuesday, 28 September 2010

08:00 – 19:00
Registration
Grand Ballroom Foyer
North Tower, M4

08:30 – 12:00
One Stop Shop for Toolkits: A Skill Building and Introductory Session to Toolkits on Community Engagement and CABs, Stakeholders’ Outreach and Education, and Clinical Processes and Operations
Dogwood A
North Tower, M1
Open Session

Host Institutions: International AIDS Vaccine Initiative (IAVI), HIV Vaccine Trials Network (HVTN), South African AIDS Vaccine Initiative (SAAVI), AVAC: Global Advocacy for HIV Prevention (AVAC)

Session Chairs: Prince Bahati (IAVI), Heather Clark (IAVI), Sarah Alexander (HVTN), Steve Wakefield (HVTN), Deirdre Grant (AVAC), Fundiswa Kibido (SAAVI), and Loraine Mohosana (SAAVI)

A number of tools have been developed by organizations in collaboration with clinical research partners that aim to support the ethical and effective conduct of HIV vaccine research. This session brings expertise from four organizations (AVAC, IAVI, HVTN and SAAVI) together to introduce innovative and field tested tools, build skills using specific tools through a participatory approach, and discuss modalities for capacity building and wider dissemination of toolkits. Tools that facilitate effective community engagement, education, quality of clinical trial processes and operations, and advocacy and communications will be introduced.

08:30 – 12:00
Preparing for the Availability of a Partially Effective HIV Vaccine
Dogwood B
North Tower, M1
Open Session

Host Institution: Centers for Disease Control and Prevention (CDC)

Session Chairs: Robert Chen, Catherine Hankins, Jose Esparza, Dawn Smith, and Lauri Markowitz

The RV144 trial showed that a partially effective vaccine against HIV acquisition is possible; overall efficacy may have been as high as 60% during the first year after immunization. Past mathematical models have shown HIV vaccines with effectiveness >30% (assuming no compensatory risk behavior) may have an important public health impact. While we’re still years away from a licensed vaccine, what might be some current “downstream” considerations for the implementation of a partially effective HIV vaccine in the developed and developing world? Are there any changes since we last considered this issue in 2002 (while awaiting the Vaxgen Phase 3 trial results)? How do the mathematical models updated with the RV144 results and other relevant parameters look? Are there lessons from the implementation of a hepatitis B vaccine (HBV) among high-risk populations, human papillomavirus (HPV) vaccine in adolescents, annual influenza vaccination, or preparations for implementation of pre-exposure prophylaxis?
SATELLITE SESSIONS
Tuesday, 28 September 2010

Exposed Uninfected and HIV Controllers: Models for Preventive and Therapeutic Vaccines?

Host Institutions: National Institute of Health (NIH) and the French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Session Chairs: Gianfranco Pancino and Bruce Walker

The satellite meeting on HIV controllers at AIDS Vaccine 2009 outlined the relevance of this model for vaccine research. The 2010 satellite will broaden this topic to another highly relevant model of protection against HIV infection: the HIV exposed yet uninfected individual. The main goals of the meeting are to: update our knowledge in the two fields to the more recent results, compare and discuss the mechanisms of control of HIV infection in the two models, focusing on innate and adaptive immune responses, and to infer new hints potentially useful to drive the research for new vaccine strategies.

Diversifying the Pipeline of Product Concepts for an HIV Vaccine: Collaboration for AIDS Vaccine Discovery (CAVD) RFP Overview and Q & A

Host Institution: The Bill & Melinda Gates Foundation

Session Chairs: Jose Esparza, Nina Russell, Francine McCutchan, and Siobhan Malone

This satellite session will provide interested AIDS Vaccine 2010 attendees with an opportunity to learn more about the Collaboration for AIDS Vaccine Discovery (CAVD) model for collaboration as well as to provide an update on the scientific progress made in the four years since the effort first began. The Bill & Melinda Gates Foundation launched the CAVD in July 2006 with grants to 16 institutions to create an international network of highly collaborative research consortia focused on accelerating the pace of HIV vaccine development. Since its launch, the CAVD has been expanded to include 20 grantees, and each of those grantees is working with a number of collaborating institutions. In total, the CAVD currently includes 101 collaborating institutions in 21 countries involving over 450 investigators, with funding totaling more than US$355 million. Three institutions funded through the foundation’s Grand Challenges in Global Health program are also collaborating within the framework of the CAVD.
**Host Institution:** AVAC: Global Advocacy for HIV Prevention

**Session Chair:** Mitchell Warren, (AVAC)

The best approach to HIV prevention is one that provides the most options, and there remains an urgent need to expand the range of options. As prevention science and the epidemic have evolved, there is an increasing convergence in biomedical prevention research. This session will explore recent advances in ARV-based prevention research and the implications for AIDS vaccine research. Presenters will provide updates on ARV-based prevention and vaccine research and engage in a moderated discussion on opportunities and challenges for cooperation and integration in basic science, product development, product combinations, trial site infrastructure and clinical trial design and implementation.

**Host Institution:** Emory University

**Session Chairs:** Paula Frew, Dâzon Dixon Diallo, and Patrick Kelly

This meeting will focus on the development of effective mechanisms for HIV vaccine research partnerships. We will highlight key issues confronting HIV vaccine research, including community attitudes towards recent vaccine trial results and combination prevention strategies; discuss current debates on the design of placebo-controlled vaccine trials if other prevention strategies (e.g., PrEP) are found to be effective; discuss how to manage the different stages of vaccine trials; and explore changing attitudes toward shifting recommendations in ART initiation and how this will affect vaccine trials. Session attendance by community members and investigators working in the HIV vaccine research field is encouraged.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 19:00</td>
<td>Registration</td>
<td></td>
<td>Grand Ballroom Foyer North Tower, M4</td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td>Opening Session</td>
<td></td>
<td>Grand Ballroom North Tower, M4</td>
</tr>
<tr>
<td>16:30 – 16:35</td>
<td></td>
<td>Eric Hunter</td>
<td>Emory University Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>16:35 – 16:40</td>
<td></td>
<td>Alan Bernstein</td>
<td>Global HIV Vaccine Enterprise New York, New York, USA</td>
</tr>
<tr>
<td>16:40 – 17:00</td>
<td></td>
<td>Thomas Frieden</td>
<td>Centers for Disease Control Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>17:00 – 17:10</td>
<td></td>
<td>Kathleen Sebelius</td>
<td>United States Department of Health and Human Services Washington, DC, USA</td>
</tr>
<tr>
<td>17:10 – 17:25</td>
<td></td>
<td>The Atlanta Gay Men’s Chorus</td>
<td></td>
</tr>
<tr>
<td>17:25 – 17:40</td>
<td></td>
<td>Dázon Dixon Diallo</td>
<td>Sisterlove, Inc. Atlanta, Georgia, USA</td>
</tr>
</tbody>
</table>
17:40–17:55 Malegapuru William Magkoba
University of KwaZulu-Natal
KwaZulu-Natal, South Africa

17:55–18:30 The Path to an HIV Vaccine: Follow the Science
OS.01
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, Maryland, USA

18:30–20:00 Welcome Reception
South Tower, Atrium Terrace
07:30 – 18:00  Registration
Grand Ballroom Foyer
North Tower, M4

08:00 – 09:35  Plenary Session 01: Improving Immunogens and Delivery
Grand Ballroom
North Tower, M4
Chairs: Gary Nabel and Souleymane Mboup

08:00 – 08:05  Welcome Remarks
James W. Wagner
President of Emory University
Atlanta, Georgia, USA

08:05 – 08:35  Clues from the Isolation and Structural Analysis of Broadly Neutralizing Anti-HIV-1 Antibodies
John Mascola
Vaccine Research Center, NIAID, NIH
Bethesda, Maryland, USA

08:35 – 09:05  Designing Vaccine Inserts with Enhanced Potential to Contend with HIV Diversity
Bette Korber
Theoretical Biology, Los Alamos National Laboratory
Los Alamos, New Mexico, USA

Giuseppe Pantaleo
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland

09:35 – 10:00  Coffee Break
Grand Ballroom Foyer
North Tower, M4
10:00 – 12:00  
**Oral Abstract Session 01:**  
**Novel Immunogens and Inserts**  
Chairs: Nancy Haigwood and Tomas Hanke  

---

10:00 – 10:15  
**A Global AIDS Vaccine Based on Conserved Elements of the Viral Proteome**  
James Mullins  
University of Washington  
Seattle, Washington USA  

10:15 – 10:30  
**Codon Optimization of HIV-1 Vaccines Decreases the Potential Breadth of CD8+ T-Cell Responses**  
Anne Bet  
University of Alabama at Birmingham  
Birmingham, Alabama, USA  

10:30 – 10:45  
**Co-delivery of Mucosal Chemokine Plasmids in Systemically Administered DNA Vaccines Elicits Systemic and Mucosal Immune Responses in Rhesus Macaques**  
Michele Kutzler  
Drexel University College of Medicine  
Philadelphia, Pennsylvania, USA  

10:45 – 11:00  
**Control of Pathogenic SIVmac239 Following Electroporated DNA + IL-12 Prime and Adenovirus 5 Boost in the NHP Model**  
Adrian McDermott  
International AIDS Vaccine Initiative (IAVI)  
Brooklyn, New York, USA  

11:00 – 11:15  
**Prevention of Systemic Infection by a Multigenic Recombinant Protein Vaccine after Heterologous R5 Clade C SHIV Challenge: Correlates of Protection**  
Robert Rasmussen  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA
11:15 – 11:30  Sustainable High Titer Neutralizing Antibodies are Rapidly Induced by Novel Virus-Like Particles when Combined with DNA Vaccines in Rabbits
Shelly Krebs
Oregon Health and Sciences University
Beaverton, Oregon, USA

11:30 – 11:45  Indicators of Therapeutic Vaccine Effect Using GTU®-MultiHIV B clade DNA in Treatment-naïve Subtype C HIV-1 Infected Subjects
Eftyhia Vardas
University of Stellenbosch
Johannesburg, South Africa

11:45 – 12:00  Improved Immunogenicity Against HIV-1 Clade C Antigens by Using NYVAC-C with Restored Replication Competence
Petra Mooij
Biomedical Primate Research Centre
Rijswijk, Netherlands

10:00 – 12:00  Oral Abstract Session 02: T-cell Immunity and Immune Escape
North Tower, M4
Chairs: Todd Allen and Lisa Chakrabarti

10:00 – 10:15  CTL Escape and Reversion in HIV-1 Gag, Pol and Nef in an African Subtype C Cohort
Malinda Schaefer
Emory University
Atlanta, Georgia, USA

10:15 – 10:30  High Magnitude and Multifunctionality Epitope-specific CD8+ T-cell Responses are Associated with Selection of Escape Mutants in Acute HIV Infection
Guido Ferrari
Duke University Medical Center
Durham, North Carolina, USA

AIDS Vaccine 2010 19
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 10:45</td>
<td>Escape from Neutralization is a Frequent Event in HIV-2 Infection and is Strongly Associated with X4 Tropism</td>
<td>José Maria Marcelino</td>
<td>Instituto de Higiene e Medicina Tropical Lisboa, Portugal</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Modulation of Cytolytic Activity of CD8+ T cells by HIV-1-specific IL21+ CD4+ T cells</td>
<td>Hendrik Streeck</td>
<td>Ragon Institute of MGH, MIT and Harvard Charlestown, Massachusetts, USA</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>A Potential Role for T-bet in Eliciting the Increased Cytotoxic Potential Demonstrated by HIV-specific CD8+ T-cells in HIV Elite Controllers</td>
<td>Adam R. Hersperger</td>
<td>University of Pennsylvania Philadelphia, Pennsylvania, USA</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Dominant Clonotypes Within HIV-specific T cell Responses Display an Exhaustion Phenotype and Reduced Epitope Cross-Reactivity</td>
<td>Joseph Conrad</td>
<td>Vanderbilt University Nashville, Tennessee, USA</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Modulation of TCR Avidity of Primary HIV-1-Specific CD8 T-cell Responses by Early and Potent Antiviral Therapy Responses</td>
<td>Alexandre Harari</td>
<td>Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland</td>
</tr>
<tr>
<td>11:45 – 12:00</td>
<td>The Glycan Shield of HIV-1 is Composed of an Extended, Non-self Carbohydrate Array that is Highly Conserved Between Geographically Divergent Clades</td>
<td>Camille Bonomelli</td>
<td>Oxford University, Glycobiology Institute Oxford, United Kingdom</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>10:00 – 10:15</td>
<td>Oral Abstract Session 03: Results and Insights from Advanced Clinical Trials</td>
<td>Psychosocial Consequences of Participation in HIV Preventive Vaccine Trials: a Cross-sectional Study in ANRS COV1–COHVAC Cohort</td>
<td>Christine Durier</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td></td>
<td>“Speaking the Dialect”: Understanding Public Discourse in the Aftermath of an Early HIV Vaccine Trial Termination</td>
<td>Peter A. Newman</td>
</tr>
<tr>
<td>10:30 – 10:45</td>
<td></td>
<td>False HIV Seropositive Among Uninfected HIV Vaccine Recipients of Phase III Vaccine Trial in Thailand</td>
<td>Sutchana Tabprasit</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td></td>
<td>Exploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial</td>
<td>Jaranit Kaewkungwal</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td></td>
<td>Analysis of the Relative Risk of HIV Acquisition Among Step Study Participants with Extended Follow-up</td>
<td>Ann Duerr</td>
</tr>
</tbody>
</table>
11:15 – 11:30  
**Optimal Priming of Poxvirus Vector (NYVAC)-Based HIV Vaccine Regimens Requires 3 DNA Injections. Results of the EV03/ANRS Vac20 Phase I/II Trial**  
Giuseppe Pantaleo  
Centre Hospitalier Universitaire Vaudois (CHUV)  
Lausanne, Vaud, Switzerland

11:30 – 11:45  
**Broad and Strong Immune Responses in a Trial of a Heterologous DNA Prime MVA Boost HIV Vaccine Among Healthy Tanzanian Volunteers**  
Said Aboud  
Muhimbili University of Health and Allied Sciences  
Dar es Salaam, United Republic of Tanzania

11:45 – 12:00  
**Vaccine-induced Seropositivity (VISP) Following Immunization of Healthy Individuals with HIV DNA and Recombinant Modified Vaccinia Virus Ankara**  
Andreas Bråve  
Swedish Institute for Infectious Disease Control and Karolinska Institute  
Solna, Sweden

12:00 – 13:00  
**Lunch**  
South Tower, Atrium Terrace

12:00 – 13:00  
**Young and Early-Career Investigators Networking Lunch**  
Pine Room  
South Tower, Atrium Terrace

Young and early-career investigators whose surnames start with A-K are invited to spend lunch in the Pine Room and network with senior researchers. A list of featured researchers is available at the registration desk.
13:00 – 14:30  Oral Abstract Session 04: Acute Infection/Viral Diversity
Chairs: James Mullins and Thumbi Ndung’u

Grand Ballroom ABC
North Tower, M4

13:00 – 13:15  HIV-1 Acute Infection: Evidence of Selection?  
Morgane Rolland  
University of Washington  
Seattle, Washington, USA  

13:15 – 13:30  Molecular Targets and Potency of HIV-1 Neutralization Revealed by Dynamic Assessment of Transmitted/Founder Virus Antibody Recognition and Escape  
Katharine Bar  
University of Alabama at Birmingham  
Birmingham, Alabama, USA  

13:30 – 13:45  Early Appearance of ADCC- and ADCVI-Mediating Antibody Responses Against Autologous HIV-1 Transmitted/Founder Virus  
Guido Ferrari  
Duke University Medical Center  
Durham, North Carolina, USA  

13:45 – 14:00  Ligand Dependant Increase in KIR Gene Expression in Primary HIV-1 Infection  
Ramona Moodley  
University of KwaZulu Natal  
Durban, KwaZulu Natal, South Africa  

14:00 – 14:15  Decrease in the Ratio of Infectious to Total Virions During Acute HIV-1 Infection  
Genevieve Fouda  
Duke University Medical Center  
Durham, North Carolina, USA  

14:15 – 14:30  Evolution of HIV-1 Diversity in Regions of High Viral Diversity and Implications for Vaccine Design  
Phillipe Nyambi  
New York University School of Medicine and VA Medical Center  
New York, New York, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 14:30</td>
<td>Oral Abstract Session 05: Novel Monoclonals and Structural Insights</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: John Mascola and Lynn Morris</td>
<td></td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Structural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16</td>
<td>Ian Wilson, The Scripps Research Institute, La Jolla, California, USA</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Crystal Structure of the Neutralizing Antibody HK20 in Complex with its gp41 Antigen</td>
<td>David Lutje Hulsik, Unit of Virus Host Cell Interactions (UVHCI), Grenoble, France</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>Role of Complex Carbohydrates in Human Immunodeficiency Virus Type 1 Infection and Resistance to Antibody Neutralization</td>
<td>James Binley, Torrey Pines Institute, San Diego, California, USA</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>New Broadly Neutralizing Human Monoclonal Antibodies Targeting the 2F5 Epitope</td>
<td>Zhongyu Zhu, NCI Frederick NIH, Frederick, Maryland, USA</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Isolation of Human Monoclonal Antibodies from HIV-Uninfected Subjects Immunized with gp120/NefTat/AS01B by Dual-Color Antigen–Specific B Cell Sorting</td>
<td>M. Anthony Moody, Duke University Medical Center, Durham, North Carolina, USA</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Affinity Maturation Allows VRC01-like Antibodies to Converge on a Common Mode of Effective HIV-1 Neutralization</td>
<td>Peter Kwong, Vaccine Research Center, NIAD/NIH, Bethesda, Maryland, USA</td>
</tr>
</tbody>
</table>
13:00 – 14:30  Oral Abstract Session 06: Pre-Clinical and Early Clinical Trials  
Grand Ballroom E  
North Tower, M4

13:00 – 13:15  
**HIV-1 Envelope-CD4 Receptor Complexes Elicit Broad T- and B-cell Immune Responses as well as Cross-Reactive Neutralizing Antibodies in Rhesus Macaques**  
Willy Bogers  
Biomedical Primate Research Centre  
Rijswijk, Netherlands  

OA06.01

13:15 – 13:30  
**CD40L Expressed on Virus-like Particles Adjuvants Prevention of Acquisition Mediated by a DNA/MVA Vaccine**  
Rama Amara  
Emory University  
Atlanta, Georgia, USA  

OA06.02

13:30 – 13:45  
**Enhanced Magnitude of Immune Responses Induced by SIV Antigens Delivered by Plasmid DNA via Electroporation and Boosted by Recombinant Adenovirus 5**  
David Weiner  
University of Pennsylvania  
Philadelphia, Pennsylvania, USA  

OA06.03

13:45 – 14:00  
**Preliminary Results of Safety and Immunogenicity of Ad35-GRIN/Env HIV Vaccine in HIV-uninfected Subjects (IAVI B001)**  
Jean-Louis Excler  
International AIDS Vaccine Initiative (IAVI)  
New York, New York, USA  

OA06.04

14:00 – 14:15  
**Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda (HPTN 027)**  
Huyen Cao  
California Department of Public Health  
Richmond, California, USA  

OA06.05
14:15 – 14:30
Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus HIV Subtype C boost in Indian Volunteers
Vadakkuppattu Ramanathan
Tuberculosis Research Centre
Chennai, India

14:30 – 16:00
Poster Viewing and Coffee Break
International Ballroom
North Tower, M2

14:30 – 16:00
Special Session:
The Launch of the Global HIV Vaccine Enterprise 2010 Scientific Strategic Plan for HIV Vaccine Development

This session will discuss the recently published Enterprise 2010 Scientific Strategic Plan and will reveal the strategies and activities of Enterprise stakeholders to address the priorities and cross-cutting considerations put forward in the 2010 Plan.

The Enterprise 2010 Scientific Strategic Plan is a collaboratively developed and implemented roadmap to speed and improve HIV vaccine research and development. The 2010 Plan presents a shared vision and strengthened strategy to transform the momentum and opportunities of the past five years into faster and more productive research to develop an HIV vaccine.

14:30 – 14:35
Opening Remarks
Alan Bernstein
Global HIV Vaccine Enterprise
New York, New York, USA

14:35 – 15:15
Panel Presentations
Panelists will discuss their strategies and activities to align with the 2010 Scientific Strategic Plan and address the critical issues facing the field to develop an HIV vaccine.

Anthony Fauci
National Institutes of Health NIH/NIAID
Bethesda, Maryland, USA

Catherine Hankins
UNAIDS
Geneva, Switzerland
Seth Berkley
International AIDS Vaccine Initiative
New York, New York, USA

Glenda Gray
HIV Vaccine Trials Network
Johannesburg, South Africa

José Esparza
The Bill & Melinda Gates Foundation
Seattle, Washington, USA

15:15 – 15:55
Moderated Panel Discussion
Helene Gayle
CARE USA,
U.S. Presidential Advisory Council on HIV/AIDS
Atlanta, Georgia, USA

15:55 - 16:00
Closing Remarks
Alan Bernstein
Global HIV Vaccine Enterprise
New York, New York, USA

16:00 – 17:40
Symposium 01: Novel Immunogen, Adjuvant and Vaccine Delivery Strategies
Chairs: Brigitte Autran and Wayne Koff

16:00 – 16:25
Immunogen Designs to Elicit Broadly Neutralizing Antibodies: Introduction to the Problem and Approaches for Induction Using New Reagents
Richard Wyatt
IAVI Neutralizing Antibody Center, The Scripps Research Institute
La Jolla, California, USA

16:25 – 16:50
Design of Novel CD4–binding Site Antigens
William Schief
University of Washington
Seattle, Washington, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50 – 17:15</td>
<td>Immunogen Designs to Elicit Broad and Robust Cell Mediated Immune Responses: Introduction to the Problem and Design of Antigenic Inserts for Inclusion in HIV Vaccines</td>
<td>North Tower, M4</td>
<td>Tomas Hanke, University of Oxford, Oxford, United Kingdom</td>
</tr>
<tr>
<td>17:15 – 17:40</td>
<td>Adjuvants for Induction of Cell Mediated Immune Responses</td>
<td></td>
<td>Nathalie Garçon, GlaxoSmithKline Biologicals, Wavre, Belgium</td>
</tr>
<tr>
<td>16:00 – 17:40</td>
<td>Symposium 02: Early Phase Clinical Trials</td>
<td></td>
<td>Chairs: James Kublin and Frances Priddy</td>
</tr>
<tr>
<td>16:00 – 16:25</td>
<td>DNA Vector/Electroporation Immunogenicity Trials</td>
<td></td>
<td>Sandhya Vasan, Aaron Diamond AIDS Research Center, New York, New York, USA</td>
</tr>
<tr>
<td>16:25 – 16:50</td>
<td>DNA/Vaccinia Prime Boost Immunogenicity Trials</td>
<td></td>
<td>Eric Sandström, Karolinska Institutet, Stockholm, Sweden</td>
</tr>
<tr>
<td>16:50 – 17:15</td>
<td>The Safety and Immunogenicity of HIV-1 Vaccines Based on DNA and Replication Competent Vaccinia Vector in Phase I Clinical Trial</td>
<td></td>
<td>Yiming Shao, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</td>
</tr>
<tr>
<td>17:15 – 17:40</td>
<td>Alternative Serotype Adenovirus Vectors</td>
<td></td>
<td>Dan Barouch, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA</td>
</tr>
</tbody>
</table>
Wednesday, 29 September 2010

Symposium 03: Animal Models of HIV Transmission
Chairs: Ruth Ruprecht and Guido Silvestri

16:00 – 16:25
Challenge Challenges: Considerations in the use of Non-Human Primate Models for Studies of AIDS Virus Transmission and Vaccine Evaluation
Jeffery Lifson
AIDS and Cancer Virus Program, SAIC Frederick, Inc., National Cancer Institute Frederick, Maryland, USA

16:25 – 16:50
Persistent Vectors and Early Control of Highly Pathogenic SIV
Louis Picker
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Oregon National Primate Research Center Beaverton, Oregon, USA

16:50 – 17:15
Immune Correlates of Protection
David Watkins
University of Wisconsin-Madison Madison, Wisconsin, USA

17:15 – 17:40
The Impact of TRIM5 Polymorphism on Viremia in Rhesus Macaques
Vanessa Hirsch
NIH, NIAID, LMM Bethesda, Maryland, USA

17:30 – 23:30
Banquet at the Georgia Aquarium
The aquarium is a short 5 minute walk from the Hotel. Printed walking directions are available at the registration desk.

17:30 – 19:00
Private Aquarium Viewing
19:00 – 19:30
Reception
19:30 – 21:00
Dinner
20:15 – 20:30
AIDS: Then and Now
James Curran
Emory University, USA
20:30 – 23:30
Dance and Cash Bar
### Registration
08:00 – 18:00
Grand Ballroom Foyer
North Tower, M4

### Plenary Session 02: Lessons from Host-Virus Interactions
08:30 – 10:00
Grand Ballroom
North Tower, M4
Chairs: Robin Shattock and Carolyn Williamson

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Innate-Mucosal Immune Interactions During Acute Infection</td>
<td>Ashley Haase</td>
<td>Department of Microbiology, University of Minnesota Medical School Minneapolis, Minnesota, USA</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Lessons from Early HIV Infection</td>
<td>Andrew McMichael</td>
<td>University of Oxford Oxford, Oxfordshire, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>HIV Transmission and the Role of Antibodies: Lessons from the Settings of Mother-Infant Infection and Superinfection</td>
<td>Julie Overbaugh</td>
<td>Fred Hutchinson Cancer Research Center Seattle, Washington, USA</td>
<td></td>
</tr>
</tbody>
</table>

### Coffee Break
10:00 – 10:30
Grand Ballroom Foyer
North Tower, M4
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:30</td>
<td>Oral Abstract Session 07:</td>
<td>Prevention Strategies</td>
<td>Chairs: William Kilembe and Jonathan Mermin</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>Preventive HIV Vaccine Acceptability and Behavioral Risk Compensation Among Men Who Have Sex with Men in Nigeria, Sub-Saharan Africa</td>
<td>Olusegun Busari</td>
<td>Federal Medical Centre</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ido-Ekiti, Nigeria</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Mucosal SHIV Exposures and Oral PrEP Can Induce Specific T cell Responses, and Can Have a Chemo-Vaccination Effect</td>
<td>Ellen Kersh</td>
<td>Centers for Disease Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Atlanta, Georgia, USA</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>High HIV Incidence and HBV Vaccination Uptake in a Preparatory Cohort Study Among Men who Have Sex with Men in Bangkok, Thailand, 2006-2010</td>
<td>Timothy Holtz</td>
<td>Thailand MOPH-Centers for Disease Control and Prevention Collaboration</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nonthaburi, Thailand</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>HIV Incidence and Risk Factors for Acquisition in HIV Discordant Couples in Masaka, Uganda: A Prospective HIV Vaccine Trial Feasibility Study</td>
<td>Eugene Ruzagira</td>
<td>MRC/UVRI Uganda Research Unit on AIDS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Entebbe, Uganda</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Reduction of HIV Transmission Risk While Prescribed Antiretroviral Therapy (ARVT): Misclassification of ARVT Status as a Methodological Issue</td>
<td>Patrick Sullivan</td>
<td>Emory University</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Atlanta, Georgia, USA</td>
<td></td>
</tr>
</tbody>
</table>
11:45 – 12:00  
**Cost-per-HIV Infection**  
OA07.06  
**Averted in Africa by Couples’ HIV Testing vs Antiretroviral Treatment: HIV Prevention in a 2010 Global Economy**  
Susan Allen  
Emory University/Rwanda Zambia  
HIV Research Group  
Atlanta, Georgia, USA

12:00 – 12:30  
**Current Status of Evidence Based Prevention Strategies**  
OA07.07  
Catherine Hankins  
Joint United Nations Programme on HIV/AIDS  
Geneva, Switerland

10:30 – 12:30  
**Oral Abstract Session 08: Innate and Mucosal Immunity**  
OA08.01  
**Effect of Fcγ-receptor Polymorphisms in Rhesus Macaques on SIVmac251 Setpoint Viremia**  
Jörn Schmitz  
Beth Israel Deaconess Medical Center  
Boston, Massachusetts, USA

10:45 – 11:00  
**High Titers of Cross-Clade ADCC-Mediating Antibodies are Detectable in Plasma Samples Collected from Individuals with Broadly Neutralizing Antibodies**  
Justin Pollara  
Duke University Medical Center  
Durham, North Carolina, USA

11:00 – 11:15  
**The Role of HIV-1 Peptide Specificity in Modulating KIR+ Natural Killer (NK) Cell Function**  
OA08.03  
Lena Fadda  
Ragon Institute of MGH, MIT and Harvard  
Charleston, Massachusetts, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 11:30</td>
<td>A DNA Plasmid Prime and rAd5 Boost Vaccine Regimen Applied to the Tonsils Elicits Strong Cellular and Humoral Immune Responses in Rhesus Macaques</td>
<td>Ann Duerr</td>
<td>HIV Vaccine Trials Network Seattle, Washington, USA</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Dissecting the Protective Mechanisms in Cervicovaginal Tissues of SIVmac239Δnef-Vaccinated Macaques Against Pathogenic SIV Challenge</td>
<td>Qingsheng Li</td>
<td>University of Minnesota Shoreview, Minnesota, USA</td>
</tr>
<tr>
<td>11:45 – 12:00</td>
<td>SIV Infection Results in Loss of IL-17-Producing NK Cells in Mucosal Tissues, Which Contributes to Damage to the Mucosal Barrier</td>
<td>Nichole Klatt</td>
<td>NIH/NIAID Bethesda, Maryland, USA</td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td>HIV-1 Elite Controllers Resist HIV-1 Infection via p21 (cip-1/waf-1)</td>
<td>Huabiao Chen</td>
<td>Ragon Institute of MGH, MIT, and Harvard Charlestown, Massachusetts, USA</td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>A Comparison of Systemic Innate Immune Responses to the MRKAd5/HIV and MVA/HIV Candidate HIV Vaccines</td>
<td>Erica Andersen-Nissen</td>
<td>Fred Hutchinson Cancer Research Center Seattle, Washington, USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Presenter</td>
<td>Institution</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------</td>
<td>------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>10:30 – 10:45</td>
<td>Early Plasma B Cell Responses to Transmitted HIV-1 are Directed to Envelope gp41 and Originate by the Activation of Mutated B Cell Clones</td>
<td>Hua-Xin Liao</td>
<td>Duke University</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Nonpathogenic SIV Infection of Sooty Mangabeys is not Associated with High Levels of Autologous Neutralizing Antibodies</td>
<td>Cynthia Derdeyn</td>
<td>Emory University</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>Mechanism of Neutralization by Monoclonal Antibody VRC01, a CD4 Binding Site Directed Neutralizing Antibody with Extensive Neutralization Breadth</td>
<td>Yuxing Li</td>
<td>NIH/NIAID</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Epitope Specificities of Elite Neutralizing Sera from HIV-1–Infected Individuals</td>
<td>Georgia Tomaras</td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Mapping of Residues Critical for Neutralisation by a Broadly Cross-neutralising Antibody Targeting a Quaternary Epitope on the HIV-1 Envelope</td>
<td>Daniel Sheward</td>
<td>IIDMM, University of Cape Town</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker/Institution</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>11:45 – 12:00</td>
<td><strong>Germline Variable Genes Code for Contact Residues Maintained During Affinity Maturation of Human Anti-V3 Monoclonal Antibodies Encoded by VH5-51</strong></td>
<td>Miroslaw K. Gorny, New York University School of Medicine New York, New York, USA</td>
<td></td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td><strong>Genetic Characteristics of HIV-1 Envelope Associated with Broadly Cross-Reactive Neutralizing Antibody Responses</strong></td>
<td>Ruwayhida Thebus, Division of Virology-University of Cape Town Cape Town, Western Cape, South Africa</td>
<td></td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td><strong>Mapping Defects in IgM+ B Cell Repertoire in HIV-Infected Individuals by 454-Pyrosequencing</strong></td>
<td>Li Yin, University of Florida Gainesville, Florida, USA</td>
<td></td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td><strong>Lunch</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td><strong>Young and Early-Career Investigators Networking Lunch</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Young and early-career investigators whose surnames start with L-Z are invited to spend lunch in the Pine Room and network with senior researchers. A list of featured researchers is available at the registration desk.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 – 15:00</td>
<td>Oral Abstract Session 10: B Cell Vaccine Concepts</td>
<td>Chairs: Max Cooper and Susan Moir</td>
</tr>
</tbody>
</table>
|             | Antigenicity and Immunogenicity of Transmitted/Founder HIV Envelope Oligomers Compared to Chronic HIV Envelopes | Chun-Yen Tsao  
Duke Human Vaccine Institute  
Durham, North Carolina, USA |
| 13:30 – 13:45 | Antigenicity and Immunogenicity of Transmitted/Founder HIV Envelope Oligomers Compared to Chronic HIV Envelopes | Chun-Yen Tsao  
Duke Human Vaccine Institute  
Durham, North Carolina, USA |
| 13:45 – 14:00 | Engineered Immunogen Presenting an Epitope Recognized by a Neutralizing mAb Elicits Mammalian Serum that Recapitulate the mAb's Specificity | Timothy Cardozo  
New York University  
School of Medicine  
New York, New York, USA |
| 14:00 – 14:15 | Biophysical, Antigenic and Immunological Analysis of HIV-1 Env Constructs Designed to Focus the B Cell Response on Conserved Elements | Yu Feng  
International AIDS Vaccine Initiative (IAVI)  
San Diego, California, USA |
| 14:15 – 14:30 | Computationally Identified Mutations Suspected to Cause gp120 Charge Inversion and gp41-Mediated Allosteric Effects Impact IgG1b12 Susceptibility | David Montefiori  
Duke University  
Durham, North Carolina, USA |
| 14:30 – 14:45 | Map of Broad and Narrow Neutralization in the V3 Loop Crown | David Almond  
New York University School of Medicine  
New York, New York, USA |
14:45 – 15:00 High Through-put Functional Screening of Activated B cells from 4 African Elite Neutralizers Yields a Panel of Novel Broadly Neutralizing Antibodies
Pascal Poignard
IAVI and The Scripps Research Institute
La Jolla, California, USA

13:30 – 15:00 Oral Abstract Session 11: Virology and Immunology of Transmission Chairs: Morgane Bomsel and Vanessa Hirsch

Katharina Rothwangl
Northwestern University
Chicago, Illinois, USA

13:45 – 14:00 Susceptibility of Epithelial Cells from the Human Female Upper Reproductive Tract to Infection by Transmitted/Founder HIV-1
Christina Ochsenbauer
University of Alabama at Birmingham
Birmingham, Alabama, USA

14:00 – 14:15 HIV Env Antibodies Differentially Modulate Viral Transport in Cervical Mucus
Gianguido Cianci
Northwestern University
Chicago, Illinois, USA

14:15 – 14:30 Low Dose Mucosal SIV Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys
Jinyan Liu
Harvard Medical School
Boston, Massachusetts, USA
14:30 – 14:45
Exploring HIV Transmission in the Male Genital Tract Using the Circumcised and Uncircumcised Macaque Model
Minh Dinh
Northwestern University
Chicago, Illinois, USA

14:45 – 15:00
Differences In Glycosylation Patterns but not Neutralization Sensitivity of HIV-1 Env in Acute and Chronic Infection From Heterosexual Transmission
Ronald Swanstrom
UNC Chapel Hill
Chapel Hill, North Carolina, USA

13:30 – 15:00
Round Table Discussion: Integrating Prevention Results into HIV Vaccines Trials
Chairs: Susan Buchbinder and Yves Levy

13:30 – 13:50
Changing Landscapes - Integrating Emerging Prevention Data into Clinical Trials
Ian McGowan
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, USA

13:50 – 14:10
Integrating HIV Prevention Interventions into HIV Vaccine Trial Designs: Statistical Issues
Steve Self
Fred Hutchinson Cancer Research Center
Seattle, Washington, USA

14:10 – 14:30
Ethical Frameworks and Standards of Prevention in HIV Prevention Trials
Sean Philpott
The Bioethics Program of Union Graduate College and the Mount Sinai School of Medicine
Schenectady, New York, USA
14:30 – 15:00  
**Panel Discussion**

Ian McGowan  
Sean Philpott  
Steve Self  
Mathew Rose  
The National Coalition for LGBT Health  
Washington, DC, USA

15:00 – 16:00  
**Poster Session 01 and Coffee Break**

International Ballroom  
North Tower, M2

All even numbered posters in all topics will be presented during this poster session. A poster topic directory is located in the abstract book. Even numbered poster presenters are asked to stand by their poster during Session 01.

16:00 – 18:05  
**Symposium 04:**  
**Blocking HIV/SIV Acquisition**  
Chairs: Cynthia Derdeyn and Ronald Swanstrom

16:00 – 16:25  
**Defining the Interaction of HIV with the Mucosal Barriers to Gain Insights into the Mechanisms of Sexual Transmission**  
Thomas Hope  
Northwestern University  
Chicago, Illinois, USA

16:25 – 16:50  
**Blocking Acquisition Across Mucosal Surfaces**  
Robin Shattock  
St George’s University of London  
London, United Kingdom

16:50 – 17:15  
**Mucosal gp41-Specific IgA: from Natural Protection to Protective Vaccine Design**  
Morgane Bomsel  
Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University  
Paris, France

17:15 – 17:40  
**Immune and Genetic Correlates of Vaccine Protection Against SIVsmE660 Mucosal Infection in Rhesus Monkeys**  
Norman Letvin  
Harvard Medical School  
Boston, Massachusetts, USA
### Thursday, 30 September 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:40 – 18:05</td>
<td><strong>Preclinical Studies on DNA/MVA Vaccines; Co-Expressed GM-CSF, A Strong Adjuvant for Blocking Transmission</strong></td>
<td>Grand Ballroom D</td>
<td>Harriet Robinson, GeoVax, Inc., Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>16:00 – 18:05</td>
<td><strong>Symposium 05: Linking Innate and Adaptive Immunity – the Role of Host Genetics</strong></td>
<td>North Tower, M4</td>
<td>Julie McElrath and Bruce Walker</td>
</tr>
<tr>
<td>16:00 – 16:25</td>
<td><strong>Lessons on Antiviral Control From Evolution</strong></td>
<td></td>
<td>Amalio Telenti, University of Lausanne, Lausanne, Vaud, Switzerland</td>
</tr>
<tr>
<td>16:25 – 16:50</td>
<td><strong>Manipulating Memory CD8 T Cell Differentiation in Prime-Boost Vaccination</strong></td>
<td></td>
<td>John Harty, University of Iowa, Departments of Microbiology, Pathology and Interdisciplinary Program in Immunology, Iowa City, Iowa, USA</td>
</tr>
<tr>
<td>16:50 – 17:15</td>
<td><strong>Novel Methods of Antiviral Control</strong></td>
<td></td>
<td>David Brooks, University of California, Los Angeles, Los Angeles, California, USA</td>
</tr>
<tr>
<td>17:15 – 17:40</td>
<td><strong>The Role of Immune Activation in Modulating Immunity</strong></td>
<td></td>
<td>Jason Brenchley, Lab of Molecular Microbiology/NIAD/NIH, Bethesda, Maryland, USA</td>
</tr>
<tr>
<td>17:40 – 18:05</td>
<td><strong>TRIM5 is an Innate Immune Receptor for the Capsid of HIV-1</strong></td>
<td></td>
<td>Jeremy Luban, University of Geneva, Geneva, Switzerland</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker</td>
<td>Affiliation</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>16:00 – 18:05</td>
<td><strong>Symposium 06:</strong> Recent Advances in B Cell and Protective Antibody Responses&lt;br&gt;Chairs: Sanjay K. Phogat and Georgia Tomaras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 – 16:25</td>
<td><strong>Few and Far Between: How HIV May Be Evading Antibody Avidity and What We Can Do About It</strong>&lt;br&gt;Ron Diskin&lt;br&gt;California Institute of Technology&lt;br&gt;Pasadena, California, USA</td>
<td><strong>S06.01</strong> Ron Diskin</td>
<td>California Institute of Technology</td>
</tr>
<tr>
<td>16:25 – 16:50</td>
<td><strong>Isolation of a Novel anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-specific Single B Cell Sorting</strong>&lt;br&gt;Lynn Morris&lt;br&gt;National Institute for Communicable Diseases&lt;br&gt;Johannesburg, Gauteng, South Africa</td>
<td><strong>S06.02</strong> Lynn Morris</td>
<td>National Institute for Communicable Diseases</td>
</tr>
<tr>
<td>16:50 – 17:15</td>
<td><strong>Pathways for Inducing Broad Neutralizing Antibodies: Overcoming Anergy and Targeting Germline B Cell Receptors for Generation of HIV-1 Protective Antibodies</strong>&lt;br&gt;Barton Haynes&lt;br&gt;Duke Human Vaccine Institute&lt;br&gt;Durham, North Carolina, USA</td>
<td><strong>S06.03</strong> Barton Haynes</td>
<td>Duke Human Vaccine Institute</td>
</tr>
<tr>
<td>17:15 – 17:40</td>
<td><strong>A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals</strong>&lt;br&gt;Laura Walker&lt;br&gt;The Scripps Research Institute&lt;br&gt;San Diego, California, USA</td>
<td><strong>S06.04</strong> Laura Walker</td>
<td>The Scripps Research Institute</td>
</tr>
<tr>
<td>17:40 – 18:05</td>
<td><strong>Isolation and Characterization of Neutralizing Monoclonal Antibodies Targeting the CD4 Binding Site</strong>&lt;br&gt;Xueling Wu&lt;br&gt;Vaccine Research Center, NIAID, NIH&lt;br&gt;Bethesda, Maryland, USA</td>
<td><strong>S06.05</strong> Xueling Wu</td>
<td>Vaccine Research Center, NIAID, NIH</td>
</tr>
</tbody>
</table>
18:30 – 19:30  Poster Session 02
18:30 – 20:30  Reception
International Ballroom
North Tower, M2

All odd numbered posters in all topics will be presented during this poster session. A poster topic directory is located in the abstract book. Odd numbered poster presenters are asked to stand by their poster during Session 02.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30 – 10:10 | Symposium 07: Systems Biology in HIV Vaccine Research | Systems Biology in HIV Vaccine Research  
Chairs: Rafi Ahmed and Jacques Fellay | integrating Systems Biology Approaches for Vaccine Discovery  
Michael Katze  
University of Washington  
Seattle, Washington, USA | Grand Ballroom ABC  
North Tower, M4 |  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30 – 08:55 | Integrating Systems Biology Approaches for Vaccine Discovery | S07.01  
Integrating Systems Biology Approaches for Vaccine Discovery  
Michael Katze  
University of Washington  
Seattle, Washington, USA | Michael Katze  
University of Washington  
Seattle, Washington, USA |  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:55 – 09:20 | Extracting Cell-Type-Specific Differences from Complex Tissues | S07.02  
Extracting Cell-Type-Specific Differences from Complex Tissues  
Shai Shen-Orr  
Stanford University  
Stanford, California, USA | Shai Shen-Orr  
Stanford University  
Stanford, California, USA |  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 09:20 – 09:45 | Learning Immunology from Successful Vaccines: Innate Immunity to Systems Vaccinology | S07.03  
Learning Immunology from Successful Vaccines: Innate Immunity to Systems Vaccinology  
Bali Pulendran  
Emory University  
Atlanta, Georgia, USA | Bali Pulendran  
Emory University  
Atlanta, Georgia, USA |  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 09:45 – 10:10 | Integrative Genomic Analysis of T cell Immunity to HIV | S07.04  
Integrative Genomic Analysis of T cell Immunity to HIV  
W. Nicholas Haining  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA | W. Nicholas Haining  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA |  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30 – 10:10 | Symposium 08: Bridging and Sustaining Community Partners in the Evolving Search for an AIDS Vaccine | Bridging and Sustaining Community Partners in the Evolving Search for an AIDS Vaccine  
Chairs: Catherine Hankins and William Snow | balancing Discovery and Development: How Do We Inform and Engage Communities in the Constantly Evolving Scientific Universe?  
Paula Frew  
Emory University  
Atlanta, Georgia, USA | Grand Ballroom D  
North Tower, M4 |  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30 – 08:55 | Balancing Discovery and Development: How Do We Inform and Engage Communities in the Constantly Evolving Scientific Universe? | S08.01 | balancing Discovery and Development: How Do We Inform and Engage Communities in the Constantly Evolving Scientific Universe?  
Paula Frew  
Emory University  
Atlanta, Georgia, USA | Paula Frew  
Emory University  
Atlanta, Georgia, USA |  

AIDS Vaccine 2010
08:55 – 09:20  Enrollment and Beyond: Recruiting and Retaining 16,000 Participants and What Comes Next
Nusara Thaitawat
Department of Retrovirology, US Army Medical Component Armed Forces Research Institute of Medical Sciences
Bangkok, Thailand

09:20 – 09:45  Adolescents: Still the Missing Cohort
Linda-Gail Bekker
Desmond Tutu HIV Foundation
Cape Town, South Africa

09:45 – 10:10  Making GPP Come Alive: Experiences from Implementing Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials
Gabriela Calazans¹ and Mitchell Warren²
¹Unidade de Pesquisa de Vacinas Anti-HIV - Centro de Referencia e Treinamento DST/AIDS - São Paulo HVTU
São Paulo, Brazil
²AVAC: Global Advocacy for HIV Prevention
New York, New York, USA

08:30 – 10:10  Symposium 09: A Potential Role for Binding/ADCC Antibodies in Protection Against HIV Acquisition
Chairs: Bonnie Mathieson and Kent Weinhold

08:30 – 08:50  Modulation of IgG Activity by Differential Glycosylation
Falk Nimmerjahn
University of Erlangen-Nuernberg, Institute of Genetics, Department of Biology
Erlangen, Germany
08:50 – 09:10  The Role of Fcγ Receptor Mediated Mechanisms in Protection Against HIV Mucosal Challenge
Ann Hessell
The Scripps Research Institute
La Jolla, California, USA

09:10 – 09:30  Mechanisms of Altered ADCC Inducing Antibodies in Progressive HIV Infection
Galit Alter
Ragon Institute
Charleston, Massachusetts, USA

09:30 – 09:50  Antibody-Dependent Cell-Mediated Virus Inhibition (ADCVI) Antibodies Elicited by Vaccination
Donald Forthal
University of California, Irvine School of Medicine
Irvine, California, USA

09:50 – 10:10  Unraveling Mechanisms Underlying Protective NK Cell Responses to HIV-1 Peptides: More Than ADCC?
Caroline Tiemessen
AIDS Virus Research Unit, National Institute for Communicable Diseases
Johannesburg, Gauteng, South Africa

10:10 – 10:40  Coffee Break
Grand Ballroom Foyer
North Tower, M4
10:40 – 13:10  
Grand Ballroom  
North Tower, M4  

Plenary Session 03:  
Challenges Facing AIDS Vaccine Development  
 Chairs: Kevin De Cock and Margaret “Peggy” Johnston  

10:40 – 11:10  

Correlates of Immunity:  
RV144 - Lessons Learned  
Nelson Michael  
US Military HIV Research Program (MHRP)/Walter Reed Army Institute of Research, Rockville, Maryland, USA  

11:10 – 11:40  

Systems Biology Approaches to HIV Vaccine Development  
Rafick-Pierre Sekaly  
Vaccine and Gene Therapy Institute, Port Ste Lucie, Florida, USA and the Université de Montréal, Montreal, Canada  

11:40 – 12:10  

The Need for More Efficient Efficacy Trials of HIV Vaccines  
Lawrence Corey  
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA  

12:10 – 12:40  

Using Partnerships in the Developing World to Accelerate AIDS Vaccine Development  
Seth Berkley  
International AIDS Vaccine Initiative (IAVI), New York, New York, USA  

12:40 – 13:10  

Impact of Biomedical Prevention Approaches on the Implementation of HIV Vaccine Efficacy Trials  
Salim Abdool Karim  
CAPRISA, University of KwaZulu-Natal, South Africa
13:10 – 13:30  
Closing Session

13:10 – 13:15
Closing Remarks
Eric Hunter, 2010 Conference Chair
Emory University
Atlanta, Georgia, USA

13:15 – 13:30
AIDS Vaccine 2011
Pratap Singhasivanon, 2011 Conference Chair
Mahidol University
Bangkok, Thailand
### Alphabetized Meeting Rooms

<table>
<thead>
<tr>
<th>ROOM</th>
<th>LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrium Terrace AB</td>
<td>South Tower Atrium Terrace</td>
</tr>
<tr>
<td>B</td>
<td>Breakfast and Lunch</td>
</tr>
<tr>
<td>Beechnut</td>
<td>North Tower M3</td>
</tr>
<tr>
<td>Chestnut</td>
<td>North Tower M3</td>
</tr>
<tr>
<td>Cottonwood AB</td>
<td>North Tower M1</td>
</tr>
<tr>
<td>Cypress</td>
<td>North Tower M2</td>
</tr>
<tr>
<td>Dogwood AB</td>
<td>North Tower M1</td>
</tr>
<tr>
<td>Grand Ballroom ABCDE</td>
<td>North Tower M4</td>
</tr>
<tr>
<td>Grand Ballroom Foyer</td>
<td>North Tower M4</td>
</tr>
<tr>
<td>Hazelnut</td>
<td>North Tower M3</td>
</tr>
<tr>
<td>Hickory</td>
<td>North Tower M3</td>
</tr>
<tr>
<td>International Ballroom</td>
<td>North Tower M2</td>
</tr>
<tr>
<td>International Ballroom Foyer</td>
<td>North Tower M2</td>
</tr>
<tr>
<td>Juniper</td>
<td>North Tower M2</td>
</tr>
<tr>
<td>Magnolia</td>
<td>North Tower M2</td>
</tr>
<tr>
<td>Maple ABC</td>
<td>South Tower Atrium Terrace</td>
</tr>
<tr>
<td>Oak</td>
<td>South Tower Hotel Lobby</td>
</tr>
<tr>
<td>Pine</td>
<td>South Tower Atrium Terrace</td>
</tr>
<tr>
<td>Redwood</td>
<td>North Tower M1</td>
</tr>
<tr>
<td>Sycamore</td>
<td>North Tower M2</td>
</tr>
<tr>
<td>Walnut</td>
<td>North Tower M3</td>
</tr>
<tr>
<td>Wireless Access Code</td>
<td>North Tower M1–M4</td>
</tr>
<tr>
<td></td>
<td>AV2010ATL</td>
</tr>
</tbody>
</table>
### PROGRAM AT A GLANCE

#### Tuesday, 28 September
- **08:00**
- **08:30**
- **09:30**
- **10:00**
- **10:30**
- **12:00**
- **12:30**
- **13:00**
- **13:30**
- **14:00**
- **14:30**
- **15:00**
- **16:00**
- **16:30**
- **17:30**
- **18:30**

#### Wednesday, 29 September
- **08:00**
- **08:30**
- **09:30**
- **10:00**
- **10:30**
- **12:00**
- **12:30**
- **13:00**
- **13:30**
- **14:00**
- **14:30**
- **15:00**
- **16:00**
- **16:30**
- **17:30**
- **18:30**

#### Thursday, 30 September
- **08:00**
- **08:30**
- **09:30**
- **10:00**
- **10:30**
- **12:00**
- **12:30**
- **13:00**
- **13:30**
- **14:00**
- **14:30**
- **15:00**
- **16:00**
- **16:30**
- **17:30**
- **18:30**

#### Friday, 1 October
- **08:00**
- **08:30**
- **09:30**
- **10:00**
- **10:30**
- **12:00**
- **12:30**
- **13:00**
- **13:30**
- **14:00**
- **14:30**
- **15:00**
- **16:00**
- **16:30**
- **17:30**
- **18:30**

---

**Plenary Session 01:** Improving Immunogens and Delivery
- **08:00 – 09:35**
  - James Wagner
  - John Mascola
  - Bette Korber
  - Giuseppe Pantaleo

**Coffee Break**
- **09:35 – 10:00**

**Oral Abstract 01:** Novel Immunogens and Inserts
- **10:00 – 12:00**
- Grand Ballroom Foyer, North Tower M4

**Oral Abstract 02:** T-cell Immunity and Immune Escape
- **10:00 – 12:00**
- Grand Ballroom D, North Tower M4

**Oral Abstract 03:** Results and Insights from Advanced Clinical Trials
- **10:00 – 12:00**
- Grand Ballroom E, North Tower M4

**Lunch**
- **12:00 – 13:00**
- South Tower, Atrium Terrace

**Young and Early-Career Investigators Networking Lunch A-K**
- **12:00 – 13:00**
- Pine Room, South Tower Atrium Terrace

**Oral Abstract 04:** Acute Infection/Viral Diversity
- **13:00 – 14:30**
- Grand Ballroom ABC, North Tower M4

**Oral Abstract 05:** Novel Monoclonals and Structural Insights
- **13:00 – 14:30**
- Grand Ballroom D, North Tower M4

**Oral Abstract 06:** Pre-Clinical and Early Clinical Trials
- **13:00 – 14:30**
- Grand Ballroom E, North Tower M4

**Poster Viewing and Coffee Break**
- **14:30 – 16:00**
- International Ballroom North Tower M2

**Special Session:** Launch of the Global HIV Vaccine Enterprise 2010 Scientific Strategic Plan
- **14:30 – 16:00**
- Grand Ballroom D, North Tower M4

**Symposium 01:** Novel Immunogen, Adjuvant and Vaccine Delivery Strategies
- **14:30 – 16:00**
- Grand Ballroom ABC, North Tower M4

**Symposium 02:** Early Phase Clinical Trials
- **14:30 – 16:00**
- Grand Ballroom D, North Tower M4

**Symposium 03:** Animal Models of HIV Transmission
- **14:30 – 16:00**
- Grand Ballroom E, North Tower M4

---

**Plenary Session 02:** Lessons from Host-Virus Interactions
- **16:30 – 18:00**
  - Ashely Haase
  - Andrew McMichael
  - Julie Overbaugh

**Coffee Break**
- **18:00 – 18:30**

**Oral Abstract 07:** Prevention Strategies
- **18:00 – 18:30**
- Grand Ballroom Foyer, North Tower M4

**Oral Abstract 08:** Innate and Mucosal Immunity
- **18:00 – 18:30**
- Grand Ballroom D, North Tower M4

**Oral Abstract 09:** B Cell Immunology
- **18:00 – 18:30**
- Grand Ballroom E, North Tower M4

**Lunch**
- **18:30 – 20:00**
- South Tower, Atrium Terrace

**Young and Early-Career Investigators Networking Lunch L-Z**
- **18:30 – 20:00**
- Pine Room, South Tower Atrium Terrace

**Oral Abstract 10:** B Cell Vaccine Concepts
- **19:00 – 21:00**
- Grand Ballroom ABC, North Tower M4

**Round Table Discussion:** Integrating Prevention Results Into HIV Vaccine Trials
- **19:00 – 21:00**
- Grand Ballroom D, North Tower M4

**Oral Abstract 11:** Virology and Immunology of Transmission
- **19:00 – 21:00**
- Grand Ballroom E, North Tower M4

**Poster Session 01 and Coffee Break**
- **19:00 – 21:00**
- International Ballroom, North Tower M2

---

**Plenary Session 03:** Challenges Facing AIDS Vaccine Development
- **08:30 – 10:10**
  - Nelson Michael
  - Rafick-Pierre Sekaly
  - Lawrence Corey
  - Seth Berkley
  - Salim Abdool Karim

**Closing Session**
- **10:10 – 10:40**
- Grand Ballroom, North Tower M4

**Symposium 04:** Blocking HIV/SIV Acquisition
- **10:10 – 10:40**
- Grand Ballroom E, North Tower M4

**Symposium 05:** Recent Advances in B cell and Protective Antibody Responses
- **10:10 – 10:40**
- Grand Ballroom ABC, North Tower M4

**Symposium 06:** Integrating Virology and Immunology in Protection Against HIV Acquisition
- **10:10 – 10:40**
- Grand Ballroom D, North Tower M4

---

**Banquet at the Georgia Aquarium**
- **17:30 – 20:00**
- Private Aquarium Viewing 17:30 – 19:00
- Reception 19:00 – 21:00
- Remarks, James Curran 20:15 – 20:30
- Dance and Cash Bar 20:30 – 23:30

---

**Welcome Reception**
- **18:30 – 20:00**
- South Tower, Atrium Terrace